Molecular Formula	C14H18N6O
Molecular Weight	286.33
Structure
State	solid
Clearance	* 0.80 ± 0.24 L/hr/kg [asymptomatic, HIV-1-infected adult patients receiving single (IV dose of 150 mg]
Volume of distribution	* 0.86 ± 0.15 L/kg [IV administration]
Route of elimination	Elimination of abacavir was quantified in a mass balance study following administration of a 600-mg dose of 14C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose. Renal excretion of unchanged abacavir is a minor route of elimination in humans.
Protein binding	Moderate (approximately 50%). Binding of abacavir to plasma protein was independent of concentration.
Half life	1.54 ± 0.63 hours
Absorption	Rapid and extensive after oral administration (83% bioavailability, tablet). When a 300 mg tablet is given twice daily to subjects, the peak plasma concentration (Cmax) was 3.0 ± 0.89 mcg/mL and the area under the curve (AUC 0-12 hours) was 6.02 ± 1.73 mcg•hr/mL.
Trade names	Ziagen
Description	nucleoside analog reverse transcriptase inhibitor (NRTI) to treat HIV and AIDS; a synthetic carbocyclic nucleoside; guanine analogue

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
MITOCHONDRIAL DNA METABOLIC PROCESS								185
MITOCHONDRIAL DNA METABOLIC PROCESS								194

Target	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
DNA polymerase gamma								194

Pictogram	Signal	Statements	Precautionary Statement Codes
	Warning	Aggregated GHS information provided by 39 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (89.74%): Harmful if swallowed [Warning Acute toxicity, oral] H319 (89.74%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H341 (94.87%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] H351 (92.31%): Suspected of causing cancer [Warning Carcinogenicity] H361 (94.87%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P201, P202, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P330, P337+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Disease progression

Drug interaction

Epilepsy

Hypersensitivity

Immunodeficiency

Infection

Pathogen resistance

Chills (0.12)

Pruritus (0.17)

Abdominal discomfort

Abnormal dreams

Anxiety

Asthenia

Body temperature increased

Cough

Depression

Dermatitis

Diarrhoea

Discomfort

Dizziness

Drug hypersensitivity

Fatigue

Feeling abnormal

Headache

Ill-defined disorder

Infection

Insomnia

Malaise

Musculoskeletal pain

Nausea

Neuropathy peripheral

Pain

Rash

Sleep disorder

Vomiting

((1s,4r)-4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)cyclopent-2-enyl)methanol	(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol	(+/-)-Abacavir
(+/-)-cis-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol	(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol	136470-78-5
1592U89	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)-	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-
2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)-	470A785	A807079
AB01566826_01	AC-1299	ACT03218
AK163479	AKOS024464970	Abacavir (INN)
Abacavir [INN:BAN]	Abacavir sulfate	BCP07728
BDBM50366816	C-18039	C07624
CC-23613	CHEBI:421707	CHEMBL1380
CS-1354	D07057	DB01048
EN300-258000	Epitope ID:137341	FT-0631153
HY-17423	J-700136	KS-00000XJM
MCGSCOLBFJQGHM-SCZZXKLOSA-N	MFCD00903850	MLS006010117
NCGC00164560-01	NCGC00164560-02	NSC742406
Q304330	SC-16996	SC-20023
SCHEMBL38632	SMR004701251	ST24045890
UNII-WR2TIP26VS	W-5205	WR2TIP26VS
ZINC2015928	Ziagen	Ziagen (TM)(*Succinate salt*)
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9-purinyl]-1-cyclopent-2-enyl]methanol	[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol	[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
[(1S,4R)-4-[2-azanyl-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol	[(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1-cyclopent-2-enyl]methanol	abacavir
{(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol	{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol

DrugBank Name	Abacavir
DrugBank	DB01048
CAS Number	136470-78-5, 188062-50-2
PubChem Compound	441300
KEGG Compound ID	C07624
KEGG Drug	D07057
PubChem.Substance	46505718
ChEBI	421707
PharmGKB	PA448004
ChemSpider	390063
BindingDB	50366816.0
TTD	DAP000704
Wikipedia	Abacavir
HET	1KX
DPD	11893